

**Adult CIRB - Late Phase Emphasis Meeting Agenda**

**July 2, 2020**

---

**I Continuing Review**

**A091404**, A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers (Protocol Version Date 09/10/19)

---

**II Continuing Review**

**EA6174**, STAMP: Surgically Treated Adjuvant Merkel cell Carcinoma with Pembrolizumab, a Phase III Trial (Protocol Version Date 03/05/20)

---

**III Continuing Review**

**NRG-GY021**, A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab In Platinum-Sensitive Recurrent Ovarian Cancer (Protocol Version Date 04/24/20)

---

**IV Continuing Review**

**S1500**, A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET) (Protocol Version Date 06/01/20)

---

**V New Study - Initial Review**

**EA2176**, A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naïve Metastatic Anal Cancer Patients (Protocol Version Date 05/28/20)

---



FOR THE NATIONAL CANCER INSTITUTE

## **VI New Study - Initial Review**

**EA6191**, The BAMB2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma (Protocol Version Date 06/08/20)

---

## **VII New Study - Initial Review**

**S1931**, Phase III Trial Of Immunotherapy-Based Combination Therapy With Or Without Cytoreductive Nephrectomy For Metastatic Renal Cell Carcinoma (Probe Trial) (Protocol Version Date 06/01/20)

---

## **VIII Amendment**

**A021602**, Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on Prior Therapy (CABINET) (Protocol Version Date 06/05/20)

---

## **IX Amendment**

**RTOG-1216**, Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk, Squamous Cell Cancer of the Head and Neck (Protocol Version Date 06/05/20)

---